Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Sotyktu

Immunology

Immunology Video Recap—March 11, 2026

This biweekly Immunology video recap highlights regulatory approvals,…

Immunology

Immunology Today—March 11, 2026

This week’s Immunology update highlights regulatory progress, positive…

Immunology

Immunology Weekly News - October 1st 2025

Immunology Update: EndoQuest Robotics, $1.8M NIH grant, BMS Patient Connect and…

Immunology

Immunology Weekly News - September 24th 2025

Immunology Update: Bimekizumab Durability, Icotrokinra Win, Ritlecitinib AA…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

Tags

Aortic arch disease APDS breast cancer research C3 glomerulopathy Cardiovascular Research ChatGPT Health Chugai French National Agency for the Safety of Medicines and Health Products FSGS Genitourinary Cancers Global Biosimilar Week Gyala Therapeutics Henlius Biotech Intraoperative imaging KB707 Kite Pharma LDL lifecycle management pharma Longevity Market marketing strategy medical AI MindRank neuroblastoma NSLC Oncology News online patient communities psoriatic arthritis Pulmonary diseases Rare disease advocacy Recombinant vesicular stomatitis virus Lassa vaccine regulatory affairs RSV Vaccine Samsung Health Semaglutide Nasal Spray Spinal and bulbar muscular atrophy sweetener Targeted Therapy Tvardi Therapeutics University of Queensland Vaccine adjuvants vapendavir Vista AI Weight Loss Science Yescarta Ziftomenib

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

TAGS

Aortic arch disease APDS breast cancer research C3 glomerulopathy Cardiovascular Research ChatGPT Health Chugai French National Agency for the Safety of Medicines and Health Products FSGS Genitourinary Cancers Global Biosimilar Week Gyala Therapeutics Henlius Biotech Intraoperative imaging KB707 Kite Pharma LDL lifecycle management pharma Longevity Market marketing strategy medical AI MindRank neuroblastoma NSLC Oncology News online patient communities psoriatic arthritis Pulmonary diseases Rare disease advocacy Recombinant vesicular stomatitis virus Lassa vaccine regulatory affairs RSV Vaccine Samsung Health Semaglutide Nasal Spray Spinal and bulbar muscular atrophy sweetener Targeted Therapy Tvardi Therapeutics University of Queensland Vaccine adjuvants vapendavir Vista AI Weight Loss Science Yescarta Ziftomenib

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy